Comparison · NCT03896009-242db509
AXS-07 vs Placebo: Percentage of Subjects Reporting Headache Pain Freedom
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AXS-07 vs Placebo: Percentage of Subjects Reporting Headache Pain Freedom. Trial comparisons, record NCT03896009-242db509. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03896009-242db509
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.199 | 0.164 | 0.239 | wilson | |
| Risk in group 2 | 0.067 | 0.0403 | 0.109 | wilson | |
| Risk difference, group 1 minus group 2 | 0.132 | 0.0767 | 0.18 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.96 | 1.73 | 5.09 | log | |
| Odds ratio, group 1 over group 2 | 3.45 | 1.91 | 6.24 | log | |
| Number needed to treat, for one more participant with the outcome on AXS-07 than on Placebo | 7.6 | 5.55 | 13 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AXS-07 | Taken once upon a qualifying migraine~AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine. | 85 | 428 | OG000 |
| Group 2 | Placebo | Taken once upon a qualifying migraine~Placebo: Placebo taken once upon onset of a qualifying migraine. | 14 | 209 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Subjects Reporting Headache Pain Freedom
- Description
- Absence of headache pain. AXS-07 vs Placebo.
- Time frame
- Hour 2 following dose administration
- Population
- ITT population consists of all randomized subjects who received study drug and had a qualifying migraine.
Source ClinicalTrials.gov
Trial
- Title
- Maximizing Outcomes in Treating Acute Migraine
- NCT number
- NCT03896009
- Phases
- PHASE3
- Conditions
- Migraine
- Interventions
- AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
- Lead sponsor
- Axsome Therapeutics, Inc.
- Results first posted
- 2023-08-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03896009?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03896009-242db509